BeiGene (BGNE) Expected to Post Earnings of -$1.94 Per Share

Wall Street analysts expect that BeiGene (NASDAQ:BGNE) will report ($1.94) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for BeiGene’s earnings, with the lowest EPS estimate coming in at ($2.00) and the highest estimate coming in at ($1.87). BeiGene posted earnings per share of ($1.27) in the same quarter last year, which indicates a negative year over year growth rate of 52.8%. The company is expected to issue its next quarterly earnings results on Wednesday, May 9th.

On average, analysts expect that BeiGene will report full-year earnings of ($7.69) per share for the current year, with EPS estimates ranging from ($8.60) to ($6.77). For the next fiscal year, analysts anticipate that the company will post earnings of ($7.90) per share, with EPS estimates ranging from ($8.47) to ($7.33). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover BeiGene.

How to Become a New Pot Stock Millionaire

BeiGene (NASDAQ:BGNE) last announced its quarterly earnings results on Wednesday, February 28th. The company reported ($2.19) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.40). The business had revenue of $18.17 million during the quarter, compared to the consensus estimate of $23.00 million.

A number of brokerages have issued reports on BGNE. Morgan Stanley boosted their price target on BeiGene from $93.00 to $200.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 21st. BidaskClub upgraded BeiGene from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, March 21st. Robert W. Baird reiterated a “hold” rating and set a $138.00 price target on shares of BeiGene in a research report on Thursday, March 1st. Ladenburg Thalmann reissued a “buy” rating and issued a $172.00 price objective on shares of BeiGene in a research note on Thursday, March 1st. They noted that the move was a valuation call. Finally, Maxim Group reissued a “buy” rating and issued a $160.00 price objective (up previously from $144.00) on shares of BeiGene in a research note on Thursday, March 1st. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $145.17.

BGNE stock traded up $1.75 during trading on Monday, reaching $166.23. 249,510 shares of the company’s stock were exchanged, compared to its average volume of 405,226. The company has a debt-to-equity ratio of 0.23, a quick ratio of 6.02 and a current ratio of 6.09. BeiGene has a 1-year low of $34.36 and a 1-year high of $182.79. The firm has a market capitalization of $8,810.37, a PE ratio of -74.54 and a beta of 0.22.

In other news, Director Bros. Advisors Lp Baker acquired 1,980,198 shares of the company’s stock in a transaction dated Thursday, January 18th. The shares were bought at an average price of $101.00 per share, with a total value of $199,999,998.00. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Howard Liang sold 10,872 shares of the business’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $157.07, for a total value of $1,707,665.04. Following the sale, the chief financial officer now directly owns 15,872 shares in the company, valued at $2,493,015.04. The disclosure for this sale can be found here. Insiders sold a total of 194,210 shares of company stock worth $29,041,676 in the last three months. Company insiders own 19.90% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. Bank of Montreal Can raised its position in shares of BeiGene by 3.8% during the fourth quarter. Bank of Montreal Can now owns 16,186 shares of the company’s stock worth $1,581,000 after purchasing an additional 600 shares during the period. Vident Investment Advisory LLC raised its position in shares of BeiGene by 2.6% during the third quarter. Vident Investment Advisory LLC now owns 29,191 shares of the company’s stock worth $3,020,000 after purchasing an additional 733 shares during the period. TD Asset Management Inc. raised its position in shares of BeiGene by 3.5% during the third quarter. TD Asset Management Inc. now owns 23,568 shares of the company’s stock worth $2,437,000 after purchasing an additional 800 shares during the period. Tower Research Capital LLC TRC acquired a new stake in shares of BeiGene during the fourth quarter worth $182,000. Finally, Comerica Bank acquired a new stake in shares of BeiGene during the fourth quarter worth $246,000. 51.47% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This piece was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece can be viewed at https://www.tickerreport.com/banking-finance/3344041/beigene-bgne-expected-to-post-earnings-of-1-94-per-share.html.

About BeiGene

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Get a free copy of the Zacks research report on BeiGene (BGNE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BeiGene (NASDAQ:BGNE)

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

MaidSafeCoin  Hits One Day Trading Volume of $1.94 Million
MaidSafeCoin Hits One Day Trading Volume of $1.94 Million
$0.48 Earnings Per Share Expected for State Bank Financial  This Quarter
$0.48 Earnings Per Share Expected for State Bank Financial This Quarter
Quantstamp  Hits Market Cap of $102.59 Million
Quantstamp Hits Market Cap of $102.59 Million
Critical Contrast: Generac  and Franklin Electric
Critical Contrast: Generac and Franklin Electric
Head-To-Head Analysis: Avis Budget Group  and Ryder
Head-To-Head Analysis: Avis Budget Group and Ryder
Critical Comparison: GCP Applied Technologies  and Its Competitors
Critical Comparison: GCP Applied Technologies and Its Competitors


Leave a Reply

© 2006-2018 Ticker Report. Google+.